Synthesis and Initial in Vivo Studies with [(11)C]SB-216763: The First Radiolabeled Brain Penetrative Inhibitor of GSK-3.

Quantifying glycogen synthase kinase-3 (GSK-3) activity in vivo using positron emission tomography (PET) imaging is of interest because dysregulation of GSK-3 is implicated in numerous diseases and neurological disorders for which GSK-3 inhibitors are being considered as therapeutic strategies. Previous PET radiotracers for GSK-3 have been reported, but none of the published examples cross the blood-brain barrier. Therefore, we have an ongoing interest in developing a brain penetrating radiotracer for GSK-3. To this end, we were interested in synthesis and preclinical evaluation of [(11)C]SB-216763, a high-affinity inhibitor of GSK-3 (K i = 9 nM; IC50 = 34 nM). Initial radiosyntheses of [(11)C]SB-216763 proved ineffective in our hands because of competing [3 + 3] sigmatropic shifts. Therefore, we have developed a novel one-pot two-step synthesis of [(11)C]SB-216763 from a 2,4-dimethoxybenzyl-protected maleimide precursor, which provided high specific activity [(11)C]SB-216763 in 1% noncorrected radiochemical yield (based upon [(11)C]CH3I) and 97-100% radiochemical purity (n = 7). Initial preclinical evaluation in rodent and nonhuman primate PET imaging studies revealed high initial brain uptake (peak rodent SUV = 2.5 @ 3 min postinjection; peak nonhuman primate SUV = 1.9 @ 5 min postinjection) followed by washout. Brain uptake was highest in thalamus, striatum, cortex, and cerebellum, areas known to be rich in GSK-3. These results make the arylindolemaleimide skeleton our lead scaffold for developing a PET radiotracer for quantification of GSK-3 density in vivo and ultimately translating it into clinical use.

[1]  X. Shao,et al.  Synthesis and evaluation of [(11)C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3β (GSK-3β). , 2014, Nuclear medicine and biology.

[2]  U. Rix,et al.  GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. , 2014, ACS chemical biology.

[3]  S. Hellberg,et al.  AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans , 2013, Journal of neurochemistry.

[4]  C. Pérez,et al.  Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. , 2013, ACS chemical neuroscience.

[5]  H. Weng,et al.  The Role of Glycogen Synthase Kinase 3 Beta in Neuroinflammation and Pain. , 2013, Journal of pharmaceutics & pharmacology.

[6]  Sven Hellberg,et al.  Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines. , 2012, Journal of medicinal chemistry.

[7]  Alan A. Wilson,et al.  Towards the preparation of radiolabeled 1-aryl-3-benzyl ureas: Radiosynthesis of [(11)C-carbonyl] AR-A014418 by [(11)C]CO(2) fixation. , 2012, Bioorganic & medicinal chemistry letters.

[8]  Ana Martínez,et al.  GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS , 2011, Front. Mol. Neurosci..

[9]  H. Eldar-Finkelman,et al.  Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas. , 2011, Bioorganic & medicinal chemistry letters.

[10]  Manuela G. López,et al.  The antinociceptive effects of AR-A014418, a selective inhibitor of glycogen synthase kinase-3 beta, in mice. , 2011, The journal of pain : official journal of the American Pain Society.

[11]  G. Hutchins,et al.  The first synthesis of [(11)C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3). , 2011, Bioorganic & medicinal chemistry letters.

[12]  M. Frech,et al.  Novel indolylmaleimide acts as GSK-3beta inhibitor in human neural progenitor cells. , 2010, Bioorganic & medicinal chemistry.

[13]  Jesús Avila,et al.  Role of glycogen synthase kinase-3 in Alzheimer’s disease pathogenesis and glycogen synthase kinase-3 inhibitors , 2010, Expert review of neurotherapeutics.

[14]  Simon Lovestone,et al.  The GSK3 hypothesis of Alzheimer's disease , 2008, Journal of neurochemistry.

[15]  M. Roh,et al.  Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. , 2006, Current drug targets.

[16]  S. A. Thomson,et al.  Synthesis and evaluation of novel heterocyclic inhibitors of GSK-3. , 2006, Bioorganic & medicinal chemistry letters.

[17]  L. Meijer,et al.  Synthesis and biological evaluation of novel phenylcarbazoles as potential anticancer agents. , 2006, Journal of medicinal chemistry.

[18]  Alan A. Wilson,et al.  Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): a radiolabelled glycogen synthase kinase-3beta specific inhibitor for PET studies. , 2005, Bioorganic & medicinal chemistry letters.

[19]  H. Manji,et al.  AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. , 2004, The international journal of neuropsychopharmacology.

[20]  G. Kuo,et al.  Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3β (GSK-3β) inhibitors , 2004 .

[21]  Michel Goedert,et al.  GSK3 inhibitors: development and therapeutic potential , 2004, Nature Reviews Drug Discovery.

[22]  Kirk W. Johnson,et al.  Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. , 2004, Current pharmaceutical design.

[23]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[24]  H. Manji,et al.  AR-A 014418 , a selective GSK-3 inhibitor , produces antidepressant-like effects in the forced swim test , 2004 .

[25]  S. A. Watkins,et al.  Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors. , 2003, Bioorganic & medicinal chemistry letters.

[26]  S. A. Watkins,et al.  Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles. , 2003, Bioorganic & medicinal chemistry letters.

[27]  S. A. Watkins,et al.  Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors. , 2003, Bioorganic & medicinal chemistry letters.

[28]  Ana Martínez,et al.  Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation , 2002, Medicinal research reviews.

[29]  H. Eldar-Finkelman,et al.  Glycogen synthase kinase 3: an emerging therapeutic target. , 2002, Trends in molecular medicine.

[30]  P. Cohen,et al.  GSK3 takes centre stage more than 20 years after its discovery. , 2001, The Biochemical journal.

[31]  J W Yates,et al.  Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. , 2000, Chemistry & biology.

[32]  E. Krebs,et al.  Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. , 1999, Diabetes.

[33]  J. Brion,et al.  Developmental expression and localization of glycogen synthase kinase-3β in rat brain , 1999, Journal of Chemical Neuroanatomy.

[34]  J. Woodgett,et al.  Molecular cloning and expression of glycogen synthase kinase‐3/factor A. , 1990, The EMBO journal.

[35]  S. Eguchi,et al.  Regioselectivity control in alkylation reactions of indolyl ambident anion , 1990 .

[36]  C. Pyun,et al.  Effect of solvent and cation on the reaction of organometallic derivatives of indole with methyl iodide , 1972 .

[37]  D M DUNLOP,et al.  The Antihistamine Drugs , 1949, The Journal of pharmacy and pharmacology.